The 95RGD97 sequence on the Aα Chain of fibrinogen is essential for binding to its erythrocyte receptor

Filomena A. Carvalho, Ana Filipa Guedes, Cedric Duval, Fraser L. Macrae, Luke Swithenbank, David Farrell, Robert A.S. Ariëns, Nuno C. Santos

Research output: Contribution to journalArticle

Abstract

Background: Erythrocyte aggregation, a cardiovascular risk factor, is increased by high plasma fibrinogen levels. Here, the effect of different fibrinogen mutations on binding to its human erythrocyte receptor was assessed in order to identify the interaction sites. Methods: Three fibrinogen variants were tested, specifically mutated in their putative integrin recognition sites on the Aa chain (mutants D97E, D574E and D97E/D574E) and compared with wild-type fibrinogen. Results: Atomic force microscopy-based force spectroscopy measurements showed a significant decrease both on the fibrinogen-erythrocyte binding force and on its frequency for fibrinogen with the D97E mutation, indicating that the corresponding arginine-glycine-aspartate sequence (residues 95-97) is involved in this interaction, and supporting that the fibrinogen receptor on erythrocytes has a ß3 subunit. Changes in the fibrin clot network structure obtained with the D97E mutant were observed by scanning electron microscopy. Conclusion: These findings may lead to innovative perspectives on the development of new therapeutic approaches to overcome the risks of fibrinogen-driven erythrocyte hyperaggregation.

Original languageEnglish (US)
Pages (from-to)1985-1992
Number of pages8
JournalInternational Journal of Nanomedicine
Volume13
DOIs
StatePublished - Apr 3 2018

Fingerprint

Fibrinogen
Erythrocytes
Arginine
Amino acids
Atomic force microscopy
Agglomeration
Spectroscopy
Plasmas
Scanning electron microscopy
Fibrinogen Receptors
Erythrocyte Aggregation
Mutation
Atomic Force Microscopy
Fibrin
Aspartic Acid
Integrins
Electron Scanning Microscopy
Glycine
Spectrum Analysis

Keywords

  • Atomic force microscopy
  • Erythrocyte aggregation
  • Fibrin clot
  • Fibrinogen
  • Mutant protein

ASJC Scopus subject areas

  • Biophysics
  • Bioengineering
  • Biomaterials
  • Drug Discovery
  • Organic Chemistry

Cite this

The 95RGD97 sequence on the Aα Chain of fibrinogen is essential for binding to its erythrocyte receptor. / Carvalho, Filomena A.; Guedes, Ana Filipa; Duval, Cedric; Macrae, Fraser L.; Swithenbank, Luke; Farrell, David; Ariëns, Robert A.S.; Santos, Nuno C.

In: International Journal of Nanomedicine, Vol. 13, 03.04.2018, p. 1985-1992.

Research output: Contribution to journalArticle

Carvalho, FA, Guedes, AF, Duval, C, Macrae, FL, Swithenbank, L, Farrell, D, Ariëns, RAS & Santos, NC 2018, 'The 95RGD97 sequence on the Aα Chain of fibrinogen is essential for binding to its erythrocyte receptor', International Journal of Nanomedicine, vol. 13, pp. 1985-1992. https://doi.org/10.2147/IJN.S154523
Carvalho, Filomena A. ; Guedes, Ana Filipa ; Duval, Cedric ; Macrae, Fraser L. ; Swithenbank, Luke ; Farrell, David ; Ariëns, Robert A.S. ; Santos, Nuno C. / The 95RGD97 sequence on the Aα Chain of fibrinogen is essential for binding to its erythrocyte receptor. In: International Journal of Nanomedicine. 2018 ; Vol. 13. pp. 1985-1992.
@article{40bfcded5148407caf5a1be3eb8be701,
title = "The 95RGD97 sequence on the Aα Chain of fibrinogen is essential for binding to its erythrocyte receptor",
abstract = "Background: Erythrocyte aggregation, a cardiovascular risk factor, is increased by high plasma fibrinogen levels. Here, the effect of different fibrinogen mutations on binding to its human erythrocyte receptor was assessed in order to identify the interaction sites. Methods: Three fibrinogen variants were tested, specifically mutated in their putative integrin recognition sites on the Aa chain (mutants D97E, D574E and D97E/D574E) and compared with wild-type fibrinogen. Results: Atomic force microscopy-based force spectroscopy measurements showed a significant decrease both on the fibrinogen-erythrocyte binding force and on its frequency for fibrinogen with the D97E mutation, indicating that the corresponding arginine-glycine-aspartate sequence (residues 95-97) is involved in this interaction, and supporting that the fibrinogen receptor on erythrocytes has a {\ss}3 subunit. Changes in the fibrin clot network structure obtained with the D97E mutant were observed by scanning electron microscopy. Conclusion: These findings may lead to innovative perspectives on the development of new therapeutic approaches to overcome the risks of fibrinogen-driven erythrocyte hyperaggregation.",
keywords = "Atomic force microscopy, Erythrocyte aggregation, Fibrin clot, Fibrinogen, Mutant protein",
author = "Carvalho, {Filomena A.} and Guedes, {Ana Filipa} and Cedric Duval and Macrae, {Fraser L.} and Luke Swithenbank and David Farrell and Ari{\"e}ns, {Robert A.S.} and Santos, {Nuno C.}",
year = "2018",
month = "4",
day = "3",
doi = "10.2147/IJN.S154523",
language = "English (US)",
volume = "13",
pages = "1985--1992",
journal = "International Journal of Nanomedicine",
issn = "1176-9114",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - The 95RGD97 sequence on the Aα Chain of fibrinogen is essential for binding to its erythrocyte receptor

AU - Carvalho, Filomena A.

AU - Guedes, Ana Filipa

AU - Duval, Cedric

AU - Macrae, Fraser L.

AU - Swithenbank, Luke

AU - Farrell, David

AU - Ariëns, Robert A.S.

AU - Santos, Nuno C.

PY - 2018/4/3

Y1 - 2018/4/3

N2 - Background: Erythrocyte aggregation, a cardiovascular risk factor, is increased by high plasma fibrinogen levels. Here, the effect of different fibrinogen mutations on binding to its human erythrocyte receptor was assessed in order to identify the interaction sites. Methods: Three fibrinogen variants were tested, specifically mutated in their putative integrin recognition sites on the Aa chain (mutants D97E, D574E and D97E/D574E) and compared with wild-type fibrinogen. Results: Atomic force microscopy-based force spectroscopy measurements showed a significant decrease both on the fibrinogen-erythrocyte binding force and on its frequency for fibrinogen with the D97E mutation, indicating that the corresponding arginine-glycine-aspartate sequence (residues 95-97) is involved in this interaction, and supporting that the fibrinogen receptor on erythrocytes has a ß3 subunit. Changes in the fibrin clot network structure obtained with the D97E mutant were observed by scanning electron microscopy. Conclusion: These findings may lead to innovative perspectives on the development of new therapeutic approaches to overcome the risks of fibrinogen-driven erythrocyte hyperaggregation.

AB - Background: Erythrocyte aggregation, a cardiovascular risk factor, is increased by high plasma fibrinogen levels. Here, the effect of different fibrinogen mutations on binding to its human erythrocyte receptor was assessed in order to identify the interaction sites. Methods: Three fibrinogen variants were tested, specifically mutated in their putative integrin recognition sites on the Aa chain (mutants D97E, D574E and D97E/D574E) and compared with wild-type fibrinogen. Results: Atomic force microscopy-based force spectroscopy measurements showed a significant decrease both on the fibrinogen-erythrocyte binding force and on its frequency for fibrinogen with the D97E mutation, indicating that the corresponding arginine-glycine-aspartate sequence (residues 95-97) is involved in this interaction, and supporting that the fibrinogen receptor on erythrocytes has a ß3 subunit. Changes in the fibrin clot network structure obtained with the D97E mutant were observed by scanning electron microscopy. Conclusion: These findings may lead to innovative perspectives on the development of new therapeutic approaches to overcome the risks of fibrinogen-driven erythrocyte hyperaggregation.

KW - Atomic force microscopy

KW - Erythrocyte aggregation

KW - Fibrin clot

KW - Fibrinogen

KW - Mutant protein

UR - http://www.scopus.com/inward/record.url?scp=85045300534&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045300534&partnerID=8YFLogxK

U2 - 10.2147/IJN.S154523

DO - 10.2147/IJN.S154523

M3 - Article

C2 - 29662311

AN - SCOPUS:85045300534

VL - 13

SP - 1985

EP - 1992

JO - International Journal of Nanomedicine

JF - International Journal of Nanomedicine

SN - 1176-9114

ER -